Cardiovascular drug therapy in the elderly: benefits and challenges (Q37803337)

23 August 2017

Cardiovascular drug therapy in the elderly: benefits and challenges (English)

1 reference

23 August 2017

1 reference

2

Wilbert S Aronow

1 reference

23 August 2017

3

William H Frishman

1 reference

23 August 2017

1

Jerome L Fleg

1 reference

PubMed ID

20978470

23 August 2017

language of work or name

English

0 references

publication date

26 October 2010

1 reference

Nature Reviews Cardiology

23 August 2017

1 reference

23 August 2017

8

1 reference

23 August 2017

13-28

1 reference

23 August 2017

1

1 reference

Hypertension and risk of stroke in an elderly population

23 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Mechanism of relief of pacing induced angina with oral verapamil: reduced oxygen demand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Hemodynamics and antianginal effects of high dose oral isosorbide dinitrate after chronic use

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Age as a determinant of sensitivity to warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Risk factors for intracranial hemorrhage in outpatients taking warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Fondaparinux sodium: a review of its use in the management of acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Increasing use of medicines in elderly persons: a five-year follow-up of the Kuopio 75+Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Assessing medication adherence in the elderly: which tools to use in clinical practice?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Predictors of medication adherence in the elderly.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Treatment of hypertension in patients 80 years of age or older

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Are β-Blockers Efficacious as First-line Therapy for Hypertension in the Elderly?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Chinese Trial on Isolated Systolic Hypertension in the Elderly

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Shanghai trial of nifedipine in the elderly (STONE)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Telmisartan, ramipril, or both in patients at high risk for vascular events

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Management of hyperlipidemia in older adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Updates on cytochrome P450-mediated cardiovascular drug interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Effects of combination lipid therapy in type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Statin-fibrate combination therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment dura

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Acute Coronary Care in the Elderly, Part I

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Comparison of enteric-coated aspirin and uncoated aspirin effect on bleeding time

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Prasugrel versus clopidogrel in patients with acute coronary syndromes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Effect of propranolol in patients with myocardial infarction and ventricular arrhythmia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Beta-blocker therapy in the cardiac arrhythmia suppression trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

The effect of diltiazem on mortality and reinfarction after myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Clinical pharmacokinetics of calcium antagonists. An update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Safety and efficacy of extended-release ranolazine in patients aged 70 years or older with chronic stable angina pectoris

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Diuretic combinations in refractory oedema states: pharmacokinetic-pharmacodynamic relationships

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Metabolic adverse reactions to diuretics. Clinical relevance to elderly patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Diuretic resistance predicts mortality in patients with advanced heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

The effect of digoxin on mortality and morbidity in patients with heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

The influence of kidney function, body size and age on plasma concentration and urinary excretion of digoxin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Does digoxin provide additional hemodynamic and autonomic benefit at higher doses in patients with mild to moderate heart failure and normal sinus rhythm?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Effect of carvedilol on survival in severe chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

31 March 2020

Hemostasis and ageing.

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Warfarin maintenance dosages in the very elderly.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

31 March 2020

New antithrombotic drugs

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Dabigatran versus warfarin in patients with atrial fibrillation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Aspirin for secondary prevention after acute myocardial infarction in the elderly: prescribed use and outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Ticlopidine-associated thrombotic thrombocytopenic purpura

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Variability of response to clopidogrel: possible mechanisms and clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Effect of clopidogrel added to aspirin in patients with atrial fibrillation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiolog

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

Validation of Clinical Classification Schemes for Predicting Stroke

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2010.162

31 March 2020

1 reference

12 December 2020

Effect of propranolol in reducing mortality in older myocardial infarction patients. The Beta-Blocker Heart Attack Trial experience

1 reference

12 December 2020

A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group

1 reference

12 December 2020

Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group

1 reference

12 December 2020

Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

1 reference

12 December 2020

Access to prescription drugs for Medicare beneficiaries

1 reference

12 December 2020

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial

1 reference

12 December 2020

Clofibrate and niacin in coronary heart disease

1 reference

12 December 2020

Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop

1 reference

12 December 2020

Epidemiology and risk of hypertension in the elderly: the Framingham Study

1 reference

12 December 2020

Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation

1 reference

12 December 2020

10.1038/NRCARDIO.2010.162

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

20978470